Lava Therapeutics Nv Expected To Post A Loss Of 29 Cents A Share: Earnings Preview

LAVA Therapeutics NV

14/03/2025 13:21

LAVA Therapeutics NV LVTX.OQ LVTX.O is expected to show a rise in quarterly revenue when it reports  results on March 18 (estimated) for the period ending December 31 2024

The Utrecht-based  company is expected to report a 608.2% increase in revenue to $2.5 million from $353 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for LAVA Therapeutics NV is for a loss of 29 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for LAVA Therapeutics NV is $2.00​, above​ its last closing price of $1.33. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.35
-0.33
-0.46
Missed
-39.4
Jun. 30 2024
-0.37
-0.36
-0.31
Beat
13.9
Mar. 31 2024
-0.11
-0.12
-0.02
Beat
84​
Dec. 31 2023
0.33
-0.12
-0.24
Missed
-92
​​Sep. 30 2023
-0.49
-0.49
-0.34
Beat
30.6
Jun. 30 2023
-0.47
-0.47
-0.48
Missed
-1.4​
Mar. 31 2023
-0.52
-0.52
-0.53
Missed
-1.9
Dec. 31 2022
-0.63
-0.57
Beat
10.1

This summary was machine generated March 14 at 13:21 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)